Released Aug 3, 2023, before the open
10-Q filed Aug 3, 2023, 34 days after period end · 0001171843-23-004947
Q2 2023 · 10-Q
Revenue$0.00$0.00 no prior Q2 2022 on fileno prior Q1 2023 on file
Net Income-$11.28M-$11.28M N/M vs Q2 2022N/M vs Q1 2023
EPS, diluted—
Operating Income-$13,337,000N/M
Operating Cash Flowderived-$10,113,000N/M
Free Cash Flowderived-$10,124,000N/M
What the release said
The release
Same quarter
| Metric | Q2 2023 | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|---|
| Revenue | $0.00 | — | — | — |
| Net Income | -$11.28M | -$8.49M | -$55.80M | -$5.56M |
| EPS Diluted | — | — | -$1.07 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR